Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

This study is testing a reduced-intensity stem cell transplant approach — using fludarabine and melphalan as conditioning chemotherapy — combined with novel anti-leukemia agents for patients with myeloid blood cancers (such as AML or MDS). The goal is to see whether adding these new agents to the transplant preparation can improve outcomes while keeping the treatment more tolerable than full-intensity transplant regimens. **You may be eligible if...** - You are between 18 and 75 years old - You have a myeloid blood cancer (such as AML or MDS) and are a candidate for a stem cell transplant - You have a compatible stem cell donor — either a matched sibling or an unrelated donor with an adequate HLA match - Your donor is willing and medically able to donate peripheral blood stem cells **You may NOT be eligible if...** - You do not have a suitable matched donor - Your overall health does not allow you to safely undergo a stem cell transplant - You have active uncontrolled infections - You have significant organ dysfunction that would make the conditioning regimen unsafe Talk to your doctor to see if this trial is right for you.